These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29512481)

  • 1. Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico.
    Diaz C; Lin L; Martinez LJ; Eckels KH; Campos M; Jarman RG; De La Barrera R; Lepine E; Toussaint JF; Febo I; Innis BL; Thomas SJ; Schmidt AC
    Am J Trop Med Hyg; 2018 May; 98(5):1435-1443. PubMed ID: 29512481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I Study.
    Diaz C; Koren M; Lin L; Martinez LJ; Eckels KH; Campos M; Jarman RG; De La Barrera R; Lepine E; Febo I; Vaughn DW; Wilson TM; Paris RM; Schmidt AC; Thomas SJ
    Am J Trop Med Hyg; 2020 May; 102(5):951-954. PubMed ID: 32124728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States.
    Schmidt AC; Lin L; Martinez LJ; Ruck RC; Eckels KH; Collard A; De La Barrera R; Paolino KM; Toussaint JF; Lepine E; Innis BL; Jarman RG; Thomas SJ
    Am J Trop Med Hyg; 2017 Jun; 96(6):1325-1337. PubMed ID: 28719287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Immunogenicity of an AS03
    Lin L; Lyke KE; Koren M; Jarman RG; Eckels KH; Lepine E; McArthur MA; Currier JR; Friberg H; Moris P; Keiser PB; De La Barrera R; Vaughn DW; Paris RM; Thomas SJ; Schmidt AC
    Am J Trop Med Hyg; 2020 Jul; 103(1):132-141. PubMed ID: 32342848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico.
    Bauer K; Esquilin IO; Cornier AS; Thomas SJ; Quintero Del Rio AI; Bertran-Pasarell J; Morales Ramirez JO; Diaz C; Carlo S; Eckels KH; Tournay E; Toussaint JF; De La Barrera R; Fernandez S; Lyons A; Sun W; Innis BL
    Am J Trop Med Hyg; 2015 Sep; 93(3):441-453. PubMed ID: 26175027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.
    Sirivichayakul C; Barranco-Santana EA; Esquilin-Rivera I; Oh HM; Raanan M; Sariol CA; Shek LP; Simasathien S; Smith MK; Velez ID; Wallace D; Gordon GS; Stinchcomb DT
    J Infect Dis; 2016 May; 213(10):1562-72. PubMed ID: 26704612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions.
    Moris P; Bauer KM; Currier JR; Friberg H; Eckels KH; Esquilin IO; Gibbons RV; Innis BL; Jarman RG; Simasathien S; Sun P; Thomas SJ; Watanaveeradej V
    Hum Vaccin Immunother; 2019; 15(9):2090-2105. PubMed ID: 30829100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
    Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
    Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Mazara S; Vargas M; Brose M; Rauscher M; Tuboi S; Borkowski A; Wallace D
    Lancet Infect Dis; 2018 Feb; 18(2):162-170. PubMed ID: 29122463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
    Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
    Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J
    Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and clinical development of a dengue recombinant subunit vaccine.
    Manoff SB; George SL; Bett AJ; Yelmene ML; Dhanasekaran G; Eggemeyer L; Sausser ML; Dubey SA; Casimiro DR; Clements DE; Martyak T; Pai V; Parks DE; Coller BA
    Vaccine; 2015 Dec; 33(50):7126-34. PubMed ID: 26458804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study.
    Rupp R; Luckasen GJ; Kirstein JL; Osorio JE; Santangelo JD; Raanan M; Smith MK; Wallace D; Gordon GS; Stinchcomb DT
    Vaccine; 2015 Nov; 33(46):6351-9. PubMed ID: 26384447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults.
    Manoff SB; Sausser M; Falk Russell A; Martin J; Radley D; Hyatt D; Roberts CC; Lickliter J; Krishnarajah J; Bett A; Dubey S; Finn T; Coller BA
    Hum Vaccin Immunother; 2019; 15(9):2195-2204. PubMed ID: 30427741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
    Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
    BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults.
    Gunale B; Farinola N; Yeolekar L; Shrivastava S; Girgis H; Poonawalla CS; Dhere RM; Arankalle V; Chandra Mishra A; Mehla R; Kulkarni PS
    Vaccine; 2023 Aug; 41(38):5614-5621. PubMed ID: 37532611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of purified psoralen-inactivated and formalin-inactivated dengue vaccines in mice and nonhuman primates.
    Sundaram AK; Ewing D; Blevins M; Liang Z; Sink S; Lassan J; Raviprakash K; Defang G; Williams M; Porter KR; Sanders JW
    Vaccine; 2020 Apr; 38(17):3313-3320. PubMed ID: 32184032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.
    Kirkpatrick BD; Durbin AP; Pierce KK; Carmolli MP; Tibery CM; Grier PL; Hynes N; Diehl SA; Elwood D; Jarvis AP; Sabundayo BP; Lyon CE; Larsson CJ; Jo M; Lovchik JM; Luke CJ; Walsh MC; Fraser EA; Subbarao K; Whitehead SS
    J Infect Dis; 2015 Sep; 212(5):702-10. PubMed ID: 25801652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.